Call for Abstracts

Abstracts will be selected for poster presentation at the conference. Please submit abstracts via e-mail to urologicconology@mdanderson.org. The deadline for submission is August 25, 2017. Authors of selected abstracts will be notified via e-mail by September 30, 2017.

Friday, October 13, 2017

7:30 a.m. Registration and Continental Breakfast

8:25 Welcome and Opening Remarks
Christopher G. Wood, MD
Nizar M. Tannir, MD
Brian F. Chapin, MD

Session I: Rare Genitourinary Cancers and Benign Urology in the Cancer Patient
Moderator: Curtis A. Pettaway, MD

8:30 Update on the Management of Advanced Testicular Cancer
Shi-Ming Tu, MD

9:00 Update on the Management of Adrenocortical Carcinoma
Amishi Y. Shah, MD

9:30 Update on the Management of Locally Advanced and Metastatic Penile Cancer
Curtis A. Pettaway, MD

10:00 Questions and Answers

10:10 Break

10:30 Treatment of Locally Advanced Upper Tract Transitional Cell Carcinoma: The Rationale for Neoadjuvant Chemotherapy
Surena F. Matin, MD

11:00 Urinary Diversion Options After Radical Cystectomy: Tips and Tricks
William J. Graber, MD

MD Anderson Organizing Committee

Conference Chairs
Christopher G. Wood, MD
Program Chairman
Professor and Vice Chairman
Urology

Nizar M. Tannir, MD
Program Co-Chairman
Professor and Vice Chairman
Genitourinary Medical Oncology

Brian F. Chapin, MD
Program Co-Chairman
Assistant Professor
Urology

Arlene O. Sieker-Radtke, MD
Associate Professor
Genitourinary Medical Oncology

Carol Fourtunia
Administrative Coordinator
Urology

Constance C. Tierney, CMP
Manager
CME/Conference Management

Colin P. Dinney, MD
Professor and Chairman
Urology

Jose A. Karam, MD
Associate Professor
Urology

Neema Navai, MD
Assistant Professor
Urology

Curtis A. Pettaway, MD
Professor
Urology

Ana Aparicio, MD
Associate Professor
Genitourinary Medical Oncology

John W. Davis, MD
Associate Professor
Urology
Dealing With Benign Urologic Issues in the Cancer Patient: The MD Anderson Experience
William J. Graber, MD

Noon Questions and Answers

12:10 p.m. Lunch (Provided)

1:05 The Andrew C. von Eschenbach Lectureship
Introduction: Colin P. Dinney, MD; Christopher G. Wood, MD; Nizar M. Tannir, MD; Brian F. Chapin, MD

Session II: Renal Cell Carcinoma
Moderator: Jose A. Karam, MD

1:35 AUA/ASCO/EAU/NCCN Guidelines for the Small Renal Mass: Which One Should We Adopt?
Mehrad Adibi, MD

1:55 When is a Biopsy Indicated for the Small Renal Mass in 2017?
Surena F. Matin, MD

2:15 Imaging for Renal Masses: What Should We Use in 2017?
Aradhana M. Venkatesan, MD

2:35 Ablative Therapy for the Small Renal Mass: An Update
Sharjeel H. Sabir, MD

2:55 Questions and Answers

3:00 Break

3:20 Adjuvant Therapy for Renal Cell Carcinoma in 2017: Ready for Primetime?
Jose A. Karam, MD

3:40 The Role of Lymphadenectomy for Renal Cell Carcinoma in 2017: Is It Necessary?
Jeffrey J. Tomaszewski, MD

4:00 Debate: Partial Nephrectomy for T1b Renal Tumors
Pro: Christopher G. Wood, MD
Con: Surena F. Matin, MD

4:30 What is the Standard of Care and Available Options in Front Line and Second Line Therapy and Beyond for Metastatic Renal Cell Carcinoma?
Eric Jonasch, MD

4:50 What is Available for Non-Clear Cell Histology Metastatic Renal Cell Carcinoma?
Nizar M. Tannir, MD

5:10 The Promise of Immunotherapy in Metastatic Renal Cell Carcinoma and Novel and Promising Emerging Therapies
Jianjun Gao, MD, PhD

5:30 Case Presentations
Moderator: Christopher G. Wood, MD
Panel: Urologic Oncology and Medical Oncology Faculty

6:00 p.m. Welcome Reception

Saturday, October 14, 2017

7:30 a.m. Registration and Continental Breakfast

8:25 Welcome and Announcements
Christopher G. Wood, MD
Nizar M. Tannir, MD
Brian F. Chapin, MD

Session III: Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Moderator: Neema Navai, MD

8:30 Debate: What is the Best Treatment Option for Patients With Disease After Receiving BCG?
Continued Conventional Intravesical Therapy With an Altered Regimen
Ashish Kamat, MD

Novel Immunotherapeutic Agents/Gene Therapy
Colin P. Dinney, MD

Radical Cystectomy
Neema Navai, MD

8:50 Debate: What is the Best Approach to Intermediate Risk NMIBC?
Intravesical Chemotherapy
Mehrad Adibi, MD

BCG
Scott Delacroix, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator</th>
<th>Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:10</td>
<td><strong>NIMBC Case Discussions</strong></td>
<td>Ashish Kamat, MD</td>
<td>Urologic Oncology Faculty</td>
</tr>
<tr>
<td>9:25</td>
<td><strong>Muscle Invasive Bladder Cancer and Upper Tract Disease</strong></td>
<td>Neema Navai, MD</td>
<td>Urologic Oncology Faculty</td>
</tr>
<tr>
<td>9:40</td>
<td>Debate: RPLND is Mandatory During Nephroureterectomy</td>
<td>Surena F. Matin, MD</td>
<td>Jose A. Karam, MD</td>
</tr>
<tr>
<td>9:50</td>
<td>Questions and Answers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Debate: What is the Best Management for the Patient With cT2 Bladder Cancer Who Refuses Cystectomy?</td>
<td>Seungtaek Choi, MD</td>
<td>Ashish Kamat, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Trimodal Therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seungtaek Choi, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Radical TURBT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ashish Kamat, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Partial Cystectomy With PLND</strong></td>
<td>Colin P. Dinney, MD</td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td><strong>MIBC and Upper Tract Cases</strong></td>
<td>Neema Navai, MD</td>
<td>Urologic Oncology, Radiation Oncology and Medical Oncology Faculty</td>
</tr>
<tr>
<td>10:40</td>
<td>Debate: What is the Best Immunotherapy Regimen for Urothelial Cancer:</td>
<td>Jianjun Gao, MD, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PD1 or PDL1 Inhibition</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jianjun Gao, MD, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Combination Therapy With Anti CTLA4 and PD1 or PDL1 Inhibition</strong></td>
<td>Arlene O. Siefker-Radtke, MD</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Debate: What is the Best Initial Systemic Therapy?</td>
<td>Jianjun Gao, MD, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Immunotherapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jianjun Gao, MD, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td><strong>Systemic Therapy in Localized Disease Case Discussions: Managing Toxicity</strong></td>
<td>Arlene O. Siefker-Radtke, MD</td>
<td>Medical Oncology Faculty</td>
</tr>
<tr>
<td>11:40</td>
<td><strong>The Changing Landscape of Systemic Therapy: New Agents and Novel Therapies</strong></td>
<td>Arlene O. Siefker-Radtke, MD</td>
<td></td>
</tr>
<tr>
<td>11:50</td>
<td><strong>Locally Advanced and Metastatic Urothelial Cancer Case Discussions</strong></td>
<td>Amishi Y. Shah, MD</td>
<td>Urologic Oncology, Radiation Oncology and Medical Oncology Faculty</td>
</tr>
<tr>
<td>12:10</td>
<td>Questions and Answers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td>Lunch (Provided)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td>MACRA, MIPS and the Urologist: The Alphabet Soup of the Changing Healthcare Landscape and Why We Need to Know About It</td>
<td>Mehrad Adibi, MD</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td><strong>PSA Screening: A Reboot From the USPSTF</strong></td>
<td>John W. Davis, MD</td>
<td></td>
</tr>
<tr>
<td>2:15</td>
<td><strong>Critique, Questions, and Answers</strong></td>
<td>Curtis A. Pettaway, MD</td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td><strong>Challenging Cases in Prostate Biopsy Part 1</strong></td>
<td>Leonard Gomella, MD</td>
<td></td>
</tr>
<tr>
<td>2:35</td>
<td><strong>Challenging Cases in Prostate Biopsy Part 2</strong></td>
<td>John W. Davis, MD</td>
<td></td>
</tr>
</tbody>
</table>
2:50  Surgery for Localized Disease: Impact on Survivor and Quality of Life
Louis L. Pisters, MD

3:00  Critique, Questions, and Answers
Steven J. Frank, MD

3:05  Break

3:10  Control of the Primary Tumor in the Setting of Metastatic Disease: Update on Clinical Trials and What To Do Now
Brian F. Chapin, MD

3:25  Critique, Questions, and Answers
Ana Aparicio, MD; Christopher J. Logothetis, MD

3:30  Radiation Therapy for Prostate Cancer Update: A Physicists Point of View
Rajat J. Kudchadker, PhD

3:45  Critique, Questions, and Answers
Steven J. Frank, MD

3:50  High Risk Prostate Cancer: The Neoadjuvant Therapy Narrative
Eleni Efstatthiou, MD, PhD

4:05  Critique, Questions, and Answers
Ana Aparicio, MD; Christopher J. Logothetis, MD

4:10  Critique, Questions, and Answers
Brian F. Chapin, MD; John W. Davis, MD

4:15  Case Discussions
Moderator: Brian F. Chapin, MD
Panel: Mitchell S. Anscher, MD; Ana Aparicio, MD; John W. Davis, MD; Eleni Efstatthiou, MD, PhD; Steven J. Frank, MD; Curtis A. Pettaway, MD; Louis L. Pisters, MD; John F. Ward, MD

4:35  Adjourn